PL4255406T3 - Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego - Google Patents

Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego

Info

Publication number
PL4255406T3
PL4255406T3 PL20900746.7T PL20900746T PL4255406T3 PL 4255406 T3 PL4255406 T3 PL 4255406T3 PL 20900746 T PL20900746 T PL 20900746T PL 4255406 T3 PL4255406 T3 PL 4255406T3
Authority
PL
Poland
Prior art keywords
aminopentanethioic
medicament
therapy
acid
lateral sclerosis
Prior art date
Application number
PL20900746.7T
Other languages
English (en)
Inventor
Igor Anatolievich Pomytkin
Alexander Alexandrovich Malin
Original Assignee
Massey Ventures Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massey Ventures Limited filed Critical Massey Ventures Limited
Publication of PL4255406T3 publication Critical patent/PL4255406T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL20900746.7T 2020-12-04 2020-12-04 Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego PL4255406T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2020/000661 WO2022119470A1 (en) 2020-12-04 2020-12-04 (2s)-2-aminopentanethioic s-acid for use as medicament and in therapy of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
PL4255406T3 true PL4255406T3 (pl) 2026-05-04

Family

ID=76444523

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20900746.7T PL4255406T3 (pl) 2020-12-04 2020-12-04 Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego

Country Status (9)

Country Link
US (2) US12533330B2 (pl)
EP (1) EP4255406B1 (pl)
CN (1) CN117320703A (pl)
AU (1) AU2020480023A1 (pl)
CA (1) CA3207232A1 (pl)
ES (1) ES3066377T3 (pl)
HR (1) HRP20260394T1 (pl)
PL (1) PL4255406T3 (pl)
WO (1) WO2022119470A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117320703A (zh) 2020-12-04 2023-12-29 马西创投有限公司 用作药物并用于治疗肌萎缩侧索硬化症的(2s)-2-氨基硫代s戊酸
WO2026049634A1 (en) * 2024-08-26 2026-03-05 Massey Ventures Limited (2s)-2-aminopentanethioic s-acid for use in the therapy of diabetes mellitus or complications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576886A (en) * 1977-04-20 1980-10-15 Lepetit Spa Rifamycin derivatives
CA3078006C (en) * 2012-07-10 2022-04-26 Xpd Holdings, Llc Stabilized multi-functional antioxidant compounds and methods of use
CN117320703A (zh) 2020-12-04 2023-12-29 马西创投有限公司 用作药物并用于治疗肌萎缩侧索硬化症的(2s)-2-氨基硫代s戊酸

Also Published As

Publication number Publication date
ES3066377T3 (en) 2026-05-12
WO2022119470A1 (en) 2022-06-09
CA3207232A1 (en) 2022-06-09
US12533330B2 (en) 2026-01-27
CN117320703A (zh) 2023-12-29
AU2020480023A1 (en) 2023-08-03
EP4255406A1 (en) 2023-10-11
US20260137640A1 (en) 2026-05-21
HRP20260394T1 (hr) 2026-05-08
EP4255406C0 (en) 2026-03-11
US20240058285A1 (en) 2024-02-22
EP4255406B1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
MY173215A (en) Acetylcysteine compositions and methods of use thereof
HK1198278A1 (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
GEP20166455B (en) Methods of administering pirfenidone therapy
WO2012135812A3 (en) Treatment for dermatological pathologies
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
PH12014501560A1 (en) Carbamate compounds and of making and using same
ES3066377T3 (en) (2s)-2-aminopentanethioic acid for use as medicament and in therapy of amyotrophic lateral sclerosis
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
NZ701607A (en) Therapeutic use of chardonnay seed products
MX2010010954A (es) Farmaco contra cancer de higado.
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
GB201206486D0 (en) Vesicular formulations and uses thereof
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX2014002817A (es) Suspension oral.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
WO2012098342A8 (en) (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions
ZA202400915B (en) Pharmaceutical composition and use thereof
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
IN2015DN00966A (pl)
IN2014DN09092A (pl)
PH12012502185A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
PH12014500252A1 (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate